共 50 条
- [1] CCX559, an orally administered small molecule PD-L1 inhibitor for the treatment of solid tumorsCANCER RESEARCH, 2022, 82 (12)Sullivan, Kathleen M.Miao, ShichangYue, HuibinZhao, NikyLi, ChrisTai, EzraEbsworth, KarenRico, Gonzalo TapiaDe Souza, PaulSchall, TomZhang, Penglie
- [2] RESULTS FROM AN ONGOING OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL OF CCX559, AN ORALLY ADMINISTERED SMALL MOLECULE PD-L1 INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A800 - A800Tapia-Rico, GonzaloLundy, JoanneRichardson, GaryZhao, NikyEbsworth, KarenYue, HuibinMiao, ShichiangdeGoma, EmilJain, RitaSchall, ThomasSullivan, KathleenZhang, Pengliede Souza, PauldeGoma, Emil
- [3] CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunityPLOS ONE, 2023, 18 (06):Sullivan, Kathleen M. C.Vilalta, MartaErtl, Linda S.Wang, YuDunlap, CarolynEbsworth, KarenZhao, Bin N.Li, ShijieZeng, YibinMiao, ZhenhuaFan, PingchenMali, VenkatLange, ChristopherMcMurtrie, DarrenYang, JuLui, RebeccaScamp, RyanChhina, VickyKumamoto, AliceYau, SimonDang, TonEasterday, AshtonLiu, ShirleyMiao, ShichangCharo, IsraelSchall, Thomas J.Zhang, Penglie
- [4] CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.CANCER RESEARCH, 2021, 81 (13)Li, ChrisVilalta, MartaErtl, Linda S.Wang, YuZeng, YibinFan, PingchenLange, ChristopherMcMurtrie, DarrenYang, JuLui, RebeccaScamp, RyanChhina, VickyKumamoto, AliceOng, RyanDang, TonEasterday, AshtonZhao, NikyLiu, ShirleySingh, RajinderCharo, IsraelSullivan, KathleenSchall, Thomas J.Zhang, Penglie
- [5] THE SMALL MOLECULE PD-L1 INHIBITOR CCX559 PREFERENTIALLY ACCUMULATES IN TUMORS, RESULTING IN DEPLETION OF CELL-SURFACE PD-L1 IN A MURINE PRECLINICAL MODELJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A520 - A520Sullivan, KathleenErtl, LindaMiao, ZhenhuaFan, PingchenZeng, YibinDunlap, CarolynEbsworth, KarenGupta, SupritLi, Shijie ChrisDang, TonMiao, ShichangCharo, IsraelSchall, ThomasZhang, Penglie
- [6] A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2014, 20 (02) : 445 - 455Saif, Muhammad WasifTakimoto, ChrisMita, MonicaBanerji, UdaiLamanna, NicoleCastro, JanuarioO'Brien, SusanStogard, ChristopherVon Hoff, Daniel
- [7] A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Rosen, L. S.Galatin, P.Fehling, J. M.Laux, I.Dinolfo, M.Frye, J.Laird, D.Sikic, B. I.
- [8] Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumorsCANCER RESEARCH, 2017, 77Shapiro, Geoffrey I.Do, Khanh T.Tolaney, Sara M.Hilton, John F.Cleary, James M.Wolanski, AndrewBeardslee, BrianHassinger, FaithBhushan, KetkiCai, DongpoDowney, ElizabethPruitt-Thompson, SolidaBarry, Suzanne M.Kochupurakkal, BoseGeradts, JosephUnitt, ChristineD'Andrea, Alan D.Muzikansky, AlonaPiekarz, RichardDoyle, L. AustinSupko, Jeffrey
- [9] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumorsInvestigational New Drugs, 2014, 32 : 1236 - 1245A. Craig LockhartShankar SundaramJohn SarantopoulosMonica M. MitaAndrea Wang-GillamJennifer L. MoseleyStephanie L. BarberAlex R. LaneClaudine WackLaurent KassalowJean-François DedieuAlain C. Mita
- [10] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1236 - 1245Lockhart, A. CraigSundaram, ShankarSarantopoulos, JohnMita, Monica M.Wang-Gillam, AndreaMoseley, Jennifer L.Barber, Stephanie L.Lane, Alex R.Wack, ClaudineKassalow, LaurentDedieu, Jean-FrancoisMita, Alain C.